Phase 3 Clinical Study to Evaluate Efficacy and Safety of ASC(Autologous Adipose-derived Stem Cells) and Fibringlue or Fibringlue in Patients With Crohn's Fistula.: A Randomized Study
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary) ; Fibrin
- Indications Crohn's disease; Rectal fistula
- Focus Registrational; Therapeutic Use
- Sponsors Anterogen
- 23 Aug 2023 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
- 23 Aug 2023 Planned primary completion date changed from 31 Dec 2021 to 30 Jun 2024.
- 03 Sep 2021 New trial record